Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
CKD affects approximately 8-16% of the population worldwide and constitutes an ever-increasing socioeconomic burden. Greece has one of the highest end-stage renal disease incidence rates among developed countries, with a significant burden on the national health care system. The main purpose of our study is to record the treatment algorithms and disease management of patients presenting for the first time to hospital-based nephrologists with reduced eGFR and CKD diagnosis, under real-world clinical practice in Greece.
This is a multicenter, observational, prospective, national study which included patients with eGFR levels between 15 and 60 ml/min/1,73 m2, presenting for the first time to nephrologists (referred from other specialties) at 15 public hospital units. The participants were followed for 1 year. Samples for serum creatinine (GFR estimation) and urinary albumin to creatinine ratio (uACR) were collected at baseline and at 12 months, along with a detailed history of medications. Finally, Health-Related Patient Reported Quality of Life (QoL) was evaluated using the Kidney Disease Quality of Life Instrument KDQOL-SF v1.3 and the EQ-5D-5L index.
In total 305 patients were included in the analysis (median age 71 years, 68.5% males), with 40% of them categorized as CKD stage G3a and 39% G3b. 73.4% and 29.8% of patients had hypertension (HTN) and type 2 diabetes mellitus (DM), respectively. The most common causes of CKD were HTN 46.2% and DM 29.2%.
Concerning antihypertensive therapy, calcium channel blockers (CCB) were the most commonly used agents (total sample baseline/1year follow-up) (56.4%/58.6%), followed by angiotensin II receptor blockers (ARBs) (47.6%/51.0%), adrenergic receptor antagonists (29.6%/32.0%), diuretics (25.8%/28.8%) and ACE inhibitors (12.5%/13.4%). CCBs’ usage increased with CKD progression while that of ARBs’ decreased (from 64.6% at G3a to 25.4% at G4, and at 1 year, from 65.2% to 35.1%, respectively). However, mean usage during the study period remained stable.
DPP4 inhibitors were the most frequently used antidiabetics (total sample baseline/1year follow-up) (42.4/49.2%), followed by insulin (34.3/42.7%), biguanides (31.9/36.3%), SGLT2 inhibitors (15.3/35.4%), and GLP-1 agonists (15.3/20.2%). Among SGLT2i users, about two-thirds had CKD with type 2 diabetes and one-third had CKD alone. The use of SGLT2i increased steadily throughout the study period (from 11.1% in G3a, 23.2% in G3b, 4.3% in G4, and at 1 year, from 39.1% in G3a, 34.9% in G3b, 25.0% in G4]. For GLP-1a also mean usage increased steadily during follow-up (at baseline 7.8%, 16.1% to 8.7% in G3a, G3b and G4, respectively and at 1 year, 30.4%, 18.7% to 15%, respectively). Statins were administered to over 95% of patients across all timepoints.
At 1 year, eGFR levels showed a slight decline with a mean change of -0.5 (SD: 9.9) mL/min/1.73 m², p=NS. On the contrary, mean uACR showed a significant increase +100.2 (SD: 25.7) mg/g, p<0.05.
Regarding the KDQOL-SF v1.3 and EQ-5D-5L questionnaires at 1 year, most parameters presented similar levels, with no statistically significant differences from baseline in the majority of domains, suggesting a perceived improvement in overall health despite stable utility-based scores.
The results contributed to the collection of real-world data for the therapeutic patterns and the management of CKD in Greece and highlighted the need for optimization of therapeutic strategy and wider usage of medications with proven efficacy in this special group of patients, who can mostly profit from their beneficial effects, with the ultimate aim of improving clinical outcomes and quality of life for CKD patients.
